STI(300416)2024-04-24 10:53Financial Performance - The company's revenue for Q1 2024 was ¥442,438,250.22, representing a 1.03% increase compared to ¥437,935,386.08 in the same period last year[5] - Net profit attributable to shareholders decreased by 4.86% to ¥42,172,756.31 from ¥44,328,613.53 year-on-year[5] - Basic and diluted earnings per share both decreased by 4.93% to ¥0.0829 from ¥0.0872 in the same period last year[5] - Net profit for Q1 2024 was CNY 45,183,977.01, a decrease of 12.25% from CNY 51,604,410.96 in Q1 2023[23] - Total operating revenue for Q1 2024 was CNY 442,438,250.22, an increase of 1.15% compared to CNY 437,935,386.08 in Q1 2023[21] Cash Flow - The net cash flow from operating activities improved by 26.63%, reaching -¥61,500,238.43, compared to -¥83,819,825.53 in the previous year[5] - The company's cash flow from operating activities for Q1 2024 showed a significant improvement, although specific figures were not disclosed in the provided content[25] - Cash inflow from operating activities totaled 430,881,447.85, compared to 406,763,611.98 in the previous period, reflecting a growth of approximately 5.5%[27] - Cash outflow from operating activities was 492,381,686.28, slightly increased from 490,583,437.51, resulting in a stable cash outflow situation[27] - The net cash flow from financing activities dropped significantly by 67.59% to ¥98,051,523.79 from ¥302,520,078.75, reflecting reduced cash inflow from minority shareholder investments[11] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,840,316,336.93, a slight decrease of 0.19% from ¥4,849,655,503.07 at the end of the previous year[5] - Total liabilities decreased to CNY 1,845,613,243.86 in Q1 2024 from CNY 1,885,424,890.95 in Q1 2023, reflecting a reduction of 2.11%[20] - The company's long-term borrowings increased by 42.70% to ¥236,952,000.00 from ¥166,052,000.04, indicating a rise in financing activities[9] Shareholder Information - The total equity attributable to shareholders increased by 1.29% to ¥2,560,906,934.91 from ¥2,528,269,883.37 at the end of the previous year[5] - The total number of common shareholders at the end of the reporting period is 21,479[13] - The largest shareholder, Suzhou Testing Instrument, holds 31.93% of the shares, totaling 162,401,460 shares[14] - The company has repurchased a total of 4,560,393 shares, accounting for 0.90% of the total share capital, with a total transaction amount of 80,824,152.97 RMB[16] Investment and Expenses - Research and development expenses increased to CNY 35,076,322.80 in Q1 2024, compared to CNY 30,480,293.69 in Q1 2023, marking an increase of 15.4%[21] - The company reported a 550.14% increase in credit impairment losses, amounting to ¥4,613,911.75, due to an increase in the recovery of prior receivables[10] - Other income decreased by 42.70% to ¥3,025,177.38, primarily due to a reduction in government subsidies during the reporting period[10] Cash and Equivalents - The company's cash and cash equivalents at the end of the reporting period amounted to 830,706,896.92 RMB, down from 931,456,629.28 RMB at the beginning of the period[18] - The ending balance of cash and cash equivalents was 815,387,155.29, down from 1,097,496,920.24, indicating a decrease of approximately 25.7%[27]